Guangdong Jiaying Pharmaceutical Co Ltd (002198) — Tangible Net Worth Ratio
Guangdong Jiaying Pharmaceutical Co Ltd (002198) has a Tangible Net Worth Ratio of 89.2% as of March 2026. This metric is calculated by deducting intangible assets (CN¥78.65 Million) from net assets (CN¥730.39 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See 002198 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Guangdong Jiaying Pharmaceutical Co Ltd Tangible Net Worth Ratio (2004–2025)
This chart shows how Guangdong Jiaying Pharmaceutical Co Ltd's Tangible Net Worth Ratio has changed across 22 annual periods from 2004 to 2025. As of March 2026, the ratio stands at 89.2%, reflecting net assets of CN¥730.39 Million with intangible assets of CN¥78.65 Million CNY. See defensive interval ratio of Guangdong Jiaying Pharmaceutical Co Ltd to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for Guangdong Jiaying Pharmaceutical Co Ltd (2004–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Guangdong Jiaying Pharmaceutical Co Ltd from 2004 to 2025, covering 22 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see Guangdong Jiaying Pharmaceutical Co Ltd (002198) total market value.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 89.4% | CN¥717.93 Million | CN¥76.11 Million | CN¥849.23 Million | ▼ -4.5 pp |
| 2024 | 93.9% | CN¥758.22 Million | CN¥45.89 Million | CN¥838.82 Million | ▲ +0.1 pp |
| 2023 | 93.8% | CN¥762.98 Million | CN¥47.21 Million | CN¥847.56 Million | ▲ +1.0 pp |
| 2022 | 92.8% | CN¥728.42 Million | CN¥52.37 Million | CN¥846.65 Million | ▲ +1.3 pp |
| 2021 | 91.5% | CN¥684.48 Million | CN¥58.29 Million | CN¥807.34 Million | ▲ +0.9 pp |
| 2020 | 90.6% | CN¥683.01 Million | CN¥64.16 Million | CN¥808.44 Million | ▲ +1.1 pp |
| 2019 | 89.5% | CN¥663.17 Million | CN¥69.46 Million | CN¥855.94 Million | ▼ -0.9 pp |
| 2018 | 90.4% | CN¥785.35 Million | CN¥75.33 Million | CN¥889.56 Million | ▲ +1.2 pp |
| 2017 | 89.2% | CN¥749.81 Million | CN¥81.22 Million | CN¥876.61 Million | ▼ -2.0 pp |
| 2016 | 91.2% | CN¥984.87 Million | CN¥87.10 Million | CN¥1.10 Billion | ▲ +1.2 pp |
| 2015 | 90.0% | CN¥929.70 Million | CN¥92.98 Million | CN¥1.05 Billion | ▲ +1.3 pp |
| 2014 | 88.7% | CN¥863.35 Million | CN¥97.37 Million | CN¥1.04 Billion | ▼ -2.0 pp |
| 2013 | 90.7% | CN¥809.66 Million | CN¥75.32 Million | CN¥919.00 Million | ▼ -8.0 pp |
| 2012 | 98.7% | CN¥278.08 Million | CN¥3.55 Million | CN¥314.25 Million | ▲ +0.3 pp |
| 2011 | 98.5% | CN¥270.51 Million | CN¥4.17 Million | CN¥306.55 Million | ▲ +0.3 pp |
| 2010 | 98.1% | CN¥258.47 Million | CN¥4.79 Million | CN¥300.87 Million | ▲ +0.4 pp |
| 2009 | 97.8% | CN¥241.42 Million | CN¥5.40 Million | CN¥253.33 Million | ▼ -0.3 pp |
| 2008 | 98.1% | CN¥226.35 Million | CN¥4.41 Million | CN¥235.24 Million | ▲ +0.5 pp |
| 2007 | 97.6% | CN¥212.62 Million | CN¥5.11 Million | CN¥245.48 Million | ▲ +4.6 pp |
| 2006 | 93.0% | CN¥82.63 Million | CN¥5.78 Million | CN¥120.05 Million | ▲ +1.6 pp |
| 2005 | 91.4% | CN¥64.39 Million | CN¥5.55 Million | CN¥91.23 Million | ▲ +3.9 pp |
| 2004 | 87.5% | CN¥48.97 Million | CN¥6.11 Million | CN¥71.92 Million | — |